SharpX destroys pen needles and syringes in seconds via electric incineration — eliminating biohazard risk at the source, for clinics and homes alike. No sharps containers. No liability. No waste.
The Problem
The explosion of GLP-1s, insulin, biologics, and self-administered drugs has created an invisible public health emergency. Billions of used needles are discarded into household trash every year — endangering families, sanitation workers, and communities — while facilities face mounting compliance costs and liability.
Improperly discarded sharps injure sanitation workers, children, and healthcare staff — driving ED visits, infectious disease risk, and insurance exposure for facilities.
In one study, nearly 90% of insulin users threw needles directly in household trash. With 13.5M Americans self-injecting, that's billions of improperly discarded sharps annually.
Healthcare facilities pay ongoing, unpredictable fees for sharps containers, pickup schedules, and regulated biohazardous waste disposal — costs that compound as injection volumes grow.
GLP-1 drugs alone are projected to reach $100–200B in annual sales by 2030–33. Every prescription generates sharps waste. The problem is about to scale dramatically.
Our Solution
SharpX uses battery-powered electric incineration to convert used needles into ash in seconds. No exposed metal remains. EPA compliant. Safe for normal trash disposal per local rules. Built for clinics — and now, for home.
Simple battery-powered operation destroys pen needles and syringes completely — no sharps, no biohazard material, no special disposal required. Just ash.
SharpX is designed to meet EPA compliance standards for sharps disposal, mitigating biohazard risk and making working in healthcare safe and sustainable.
A compact, quiet countertop device purpose-built for the 13.5M Americans self-injecting at home. Positioned as a connected, reimbursable DME benefit for payers, GLP-1 manufacturers, and diabetes programs.
Market Opportunity
The self-injection device market is growing rapidly, driven by obesity, diabetes, and biologic therapies. GLP-1 drugs alone are on track for $100–200B in annual sales by 2030–33. Every patient who self-injects is a SharpX user. The U.S. home needle and syringe market already stands at $800M–$1B before fully accounting for GLP-1 growth.
Payers and municipalities bear downstream costs from community needlesticks, ED visits, and waste handling — making SharpX a reimbursable solution with institutional tailwinds behind it.
Cost Savings
SharpX replaces unpredictable sharps container and disposal fees with a flat monthly subscription covering the device and consumables. Most clients are cash-flow positive in the very first month compared to their current waste spend.
Because it's a simple operating expense, payments may be eligible as a tax-deductible business cost — reducing overhead further at year-end. For home users, we're positioning SharpX as a DME / sharps-management benefit that payers and GLP-1 manufacturers can subsidize.
Angel Investment Round
SharpX is positioned at the intersection of two massive growth curves — the GLP-1 explosion and the global push for safer at-home injection. We are raising our angel round to accelerate manufacturing, distribution, and payer partnerships. Join us early.
Express your interest in our current angel round. We'll follow up with our investment deck, financials, and next steps for qualified investors.
Interested in adding SharpX to your clinic, hospital, pharmacy, or home care program? Tell us about your situation and we'll reach out to discuss fit, pricing, and next steps.